177Lu-DWJ155 vs Disitamab Vedotin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: HER2 · full Non-Small Cell Lung Cancer pipeline
177Lu-DWJ155
Developed by Novartis
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2032 · NCT07660055 (registry estimate)
No aligned efficacy figure on record for this race.
Disitamab Vedotin
Marketed by RemeGen Co., Ltd. and partners
NCT04311034 · Phase 1/2 · completed
The study was an uncontrolled, open-label single-arm trial of 37 participants, so it could not compare disitamab vedotin with placebo or another treatment. Its primary outcomes were clinical tumor measures, but the primary endpoint result has not been reported.
Next expected readout: June 2027 · NCT06734182 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | 177Lu-DWJ155 | Disitamab Vedotin |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- 177Lu-DWJ155
- —Not reported
- Disitamab Vedotin
- —Not reported
OS, median
- 177Lu-DWJ155
- —Not reported
- Disitamab Vedotin
- —Not reported
ORR
- 177Lu-DWJ155
- —Not reported
- Disitamab Vedotin
- —Not reported
Duration of response, median
- 177Lu-DWJ155
- —Not reported
- Disitamab Vedotin
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
177Lu-DWJ155: no structured comparison results are available for Non-Small Cell Lung Cancer.
Disitamab Vedotin: no structured comparison results are available for Non-Small Cell Lung Cancer.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: 177Lu-DWJ155's landscape · Disitamab Vedotin's landscape